Phase II Clinical Study of the Combination Chemotherapy Regimen of Irinotecan Plus Oral Etoposide for the Treatment of Recurrent Ovarian Cancer (Tohoku Gynecologic Cancer Unit 101 Group Study)
Tadahiro Shoji(Iwate Medical University), Toru Sugiyama(St Mary's Hospital), Hideo Omi(Iwate Medical University), Tadao Takano(Tohoku University), Kenji Nakahara(Yamagata University), Eriko Takatori(Iwate Medical University), Akira Yoshizaki(Iwate Medical University), Hiroshi Nishiyama(Eli Lilly (United States)), Toshio Fujimoto(Akita University), Hirohisa Kurachi(Osaka Women's and Children's Hospital), Seisuke Kumagai(Iwate Medical University), Toru Tase(Miyagi Prefectural Hospital Organization), Nobuo Yaegashi(Tohoku University), Hideki Mizunuma(Fukushima Medical University), Yoshihito Yokoyama(Hirosaki University)
Cited by 18
Related Papers
Estrogen Induces the Akt-dependent Activation of Endothelial Nitric-oxide Synthase in Vascular Endothelial Cells
|Journal of Biological Chemistry|2001|387
The Tohoku Medical Megabank Project: Design and Mission
|Journal of Epidemiology|2016|386
Early menarche, nulliparity and the risk for premature and early natural menopause
|Human Reproduction|2017|238
Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells
|Molecular Cancer Research|2016|232